Bank of Montreal
VERV

Bank of Montreal’s Verve Therapeutics VERV Stock Holding History

Bank of Montreal’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-300
Closed -$3.37K – 3819
2025
Q2 		$3.37K Buy
+300
New +$1.71K ﹤0.01% 3432

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of Montreal's VERV Position: Q3 2025 in Review

Bank of Montreal sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 15,456 shares — an estimated $174K sold.

Bank of Montreal first reported a position in VERV in Q1 2023 and held it in 9 quarters. The position peaked at $1.4M in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Bank of Montreal reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of Montreal sold 15,456 Verve Therapeutics shares in Q3 2025, an estimated $174K.
  • Bank of Montreal first reported a position in Verve Therapeutics in Q1 2023 and held it in 9 quarters.
  • Bank of Montreal's Verve Therapeutics position peaked at $1.4M in Q4 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Bank of Montreal's 13F filing for Q3 2025, filed 13 Nov 2025.